Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic review and meta-analysis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4069-4079

  Svetitsky, Shuli ^a   Leibovici, Leonard ^a,b   Paul, Mical ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; GLYCOPEPTIDE; ORITAVANCIN; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

AGE DISTRIBUTION; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CATHETER INFECTION; CLINICAL TRIAL; DATA EXTRACTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EMPIRICISM; FEBRILE NEUTROPENIA; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; LANGUAGE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; RED MAN SYNDROME; RELAPSE; RISK ASSESSMENT; STAPHYLOCOCCUS INFECTION; SUPERINFECTION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; FEMALE; HUMANS; MALE; TEICOPLANIN; VANCOMYCIN;

EID: 70349510433     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00341-09     Document Type: Article

References (77)

1. Akan, H. 2008. Comparison of teicoplanin and vancomycin in initial empirical antibiotic regimen for febrile neutropenic patients. Trial NCT00454272. National Institutes of Health, Bethesda, MD. http://clinicaltrials. gov/.
2. Alfandari, S., C. Bonenfant, L. Depretere, and G. Beaucaire. 2007. Use of 27 parenteral antimicrobial agents in north of France hospitals. Med. Mal. Infect. 37:103-107.
3. Ansari, F., K. Gray, D. Nathwani, G. Phillips, S. Ogston, C. Ramsay, and P. Davey. 2003. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J. Antimicrob. Chemother. 52:842-848.
4. Auperin, A., C. Cappelli, E. Benhamou, A. Pinna, E. Peeters, C. Atlani, and O. Hartmann. 1997. Teicoplanin or vancomycin in febrile neutropenic children with cancer: a randomized study on cost effectiveness. Med. Mal. Infect. 27:984-988. (In French.)
5. Boucher, H. W., and G. R. Corey. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5):S344-S349.
6. Brink, A. J., G. A. Richards, R. R. Cummins, and J. Lambson. 2008. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int. J. Antimicrob. Agents 32:455-458.
7. Bucaneve, G., F. Menichetti, and A. Del Favero. 1999. Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia. Pharmacoeconomics 15:85-95. (Pubitemid 29039612)
8. Charbonneau, P., I. Harding, J. J. Garaud, J. Aubertin, F. Brunet, and Y. Domart. 1994. Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients. Intensive Care Med. 20(Suppl. 4):S35-S42.
9. Chow, A. W., P. J. Jewesson, A. Kureishi, and G. L. Phillips. 1993. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur. J. Haematol Suppl. 54:18-24.
10. Contra, T., M. Nestora, C. Scaglione, L. Madero, and M. A. Diaz. 1995. A study of teicoplanin and vancomycin in combination therapy for febrile episodes in neutropenic paediatric patient. Can. J. Infect. Dis. 6(Suppl. C):309.
11. Cony-Makhoul, P., G. Brossard, G. Marit, J. L. Pellegrin, J. Texier-Maugein, and J. Reiffers. 1990. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br. J. Haematol. 76(Suppl. 2):35-40.
12. Corey, G. R. 2008. A phase 2, randomized, double-blind, parallel-group, multinational trial of intravenous ARBELIC (TD 6424) for treatment of uncomplicated Staphylococcus Aureus bacteremia. Trial NCT00062647. National Institutes of Health, Bethesda, MD. http://clinicaltrials.gov/.
13. Corey, G. R., E. Rubinstein, T. Lalani, M. H. Kollef, A. F. Shorr, F. Genter, B. S. L., and H. D. Friedland on behalf of the Attain Study Group. 2008. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet., abstr. K-528. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
14. D'Antonio, D., T. Staniscia, R. Piccolomini, G. Fioritoni, S. Rotolo, G. Parruti, G. Di Bonaventura, A. Manna, V. Savini, M. P. Fiorilli, P. Di Giovanni, A. Francione, F. Schioppa, and F. Romano. 2004. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation. Chemotherapy 50: 81-87. (Pubitemid 38813017)
15. Deeks, J. J., D. G. Altman, and M. J. Bradburn. 2001. Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis, p. 285-312. In M. Egger, G. Davey Smith, and D. G. Altman (ed.), Systematic reviews in health care: meta-analysis in context, 2nd ed. BMJ Publication Group, London, United Kingdom.
16. Del Favero, A. 1992. The use of glycopeptides as empiric antiobiotic therapy in febrile neutropenic patients. A comparison between teicoplanin (TEI) and vancomycin (VAN). The GIMEMA-Infection Program. Leuk-Lymphoma 7(Suppl. 2):110-111.
17. European Antimicrobial Resistance Surveillance System. 2007, posting date. EARSS annual report 2007. European Antimicrobial Resistance Surveillance System. http://www.rivm.nl/earss/result/Monitoring-reports/Annual-reports.jsp.
18. Figuera, A., J. F. Tomas, L. Hernandez, M. L. Jimenez, M. J. Penarrubia, M. C. del Rey, R. Arranz, R. Camara, J. L. Lopez-Lorenzo, and J. M. Fernandez-Ranada. 1996. Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes. Rev. Clin. Esp. 196:515-522. (In Spanish.)
19. Finch, R. G., and G. M. Eliopoulos. 2005. Safety and efficacy of glycopeptide antibiotics. J. Antimicrob. Chemother. 55(Suppl. 2):ii5-ii13.
20. Fortun, J., E. Navas, J. Martinez-Beltran, J. Perez-Molina, P. Martin-Davila, A. Guerrero, and S. Moreno. 2001. Short-course therapy for rightside endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin. Infect. Dis. 33: 120-125.
21. Giamarellou, H., W. O'Riordan, H. W. Harris, S. Owen, S. Porter, and J. Loutit. 2003. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. L-739a.
22. Gilbert, D. N., C. A. Wood, R. C. Kimbrough, and the Infectious Diseases Consortium of Oregon. 1991. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob. Agents Chemother. 35:79-87.
23. Goldstein, B. P., E. Seltzer, R. Flamm, and D. Sahm. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. L-1577.
24. Harding, I., A. P. MacGowan, L. O. White, E. S. Darley, and V. Reed. 2000. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J. Antimicrob. Chemother. 45:835-841.
25. Hartman, C. S., M. M. Wasilewski, and B. M. Bates. 2008. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet., abstr. L-1514. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
26. Hernandez, L., and A. Figuera. 1995. Empiric antibiotic regimen for febrile neutropenia (FN). Imipenem plus vancomycin vs imipenem plus teicoplanin as initial therapy. Bone Marrow Transplant. 15:162. (Abstract.)
27. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144.
28. Higgins, J. P. T., and S. Green. 2008. Cochrane handbook for systematic reviews of interventions, version 5.0.0, updated February 2008. The Cochrane Collaboration, Washington, DC. www.cochrane-handbook.org.
29. Jauregui, L. E., S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, D. Krause, I. Satilovs, Z. Endzinas, J. Breaux, and W. O'Riordan. 2005. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41:1407-1415.
30. Kahne, D., C. Leimkuhler, W. Lu, and C. Walsh. 2005. Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev. 105:425-448.
31. Kallen, A. J., J. Brunkard, Z. Moore, P. Budge, K. E. Arnold, G. Fosheim, L. Finelli, S. E. Beekmann, P. M. Polgreen, R. Gorwitz, and J. Hageman. 2009. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann. Emerg. Med. 53:358-365.
32. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
33. Kureishi, A., P. J. Jewesson, M. Rubinger, C. D. Cole, D. E. Reece, G. L. Phillips, J. A. Smith, and A. W. Chow. 1991. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob. Agents Chemother. 35:2246-2252.
34. Liu, C. Y., W. S. Lee, C. P. Fung, N. C. Cheng, C. L. Liu, S. P. Yang, and S. L. Chen. 1996. Comparative study of teicoplanin vs vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin. Drug Investig. 12:80-87.
35. Lodise, T. P., J. Graves, A. Evans, E. Graffunder, M. Helmecke, B. M. Lomaestro, and K. Stellrecht. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52: 3315-3320.
36. Lodise, T. P., B. Lomaestro, J. Graves, and G. L. Drusano. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52: 1330-1336.
37. Magilner, D., M. M. Byerly, and D. M. Cline. 2008. The prevalence of community-acquired methicillin-resistant Staphylococcus aureus (CAMRSA) in skin abscesses presenting to the pediatric emergency department. N. C. Med. J. 69:351-354.
38. Mainardi, J. L., D. M. Shlaes, R. V. Goering, J. H. Shlaes, J. F. Acar, and F. W. Goldstein. 1995. Decreased teicoplanin susceptibility of methicillinresistant strains of Staphylococcus aureus. J. Infect. Dis. 171:1646-1650.
39. Maor, Y., G. Rahav, N. Belausov, D. Ben-David, G. Smollan, and N. Keller. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45:1511-1514.
40. Menichetti, F., P. Martino, G. Bucaneve, G. Gentile, D. D'Antonio, V. Liso, P. Ricci, A. M. Nosari, M. Buelli, M. Carotenuto, and the Gimema Infection Program. 1994. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies.. Antimicrob. Agents Chemother. 38:2041-2046.
41. Moise, P. A., G. Sakoulas, A. Forrest, and J. J. Schentag. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586.
42. Nadal, D., D. Ghelfi, K. Waldvogel, E. Stierli, E. Heitaer, and S. Fanconi. 1999. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1100, p. 725.
43. Nathwani, D., M. Morgan, R. G. Masterton, M. Dryden, B. D. Cookson, G. French, and D. Lewis. 2008. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J. Antimicrob. Chemother. 61:976-994.
44. National Committee for Clinical Laboratory Standards. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. M100-S17. National Committee for Clinical Laboratory Standards, Wayne, PA.
45. Neville, L. O., W. Brumfitt, J. M. Hamilton-Miller, and I. Harding. 1995. Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial. Int. J. Antimicrob. Agents 5:187-193.
46. Nucci, M., I. Biasoli, S. Braggio, R. Portugal, R. Schaffel, A. Maiolino, M. M. Loureiro, N. Spector, and W. Pulcheri. 1998. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients. Oncol. Rep. 5:1205-1209.
47. Pace, J. L., and G. Yang. 2006. Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. 71:968-980.
48. Pham Dang, C., F. Gouin, S. Touchais, C. Richard, and G. Potel. 2001. The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci. Pathol. Biol. (Paris) 49:587-596. (In French.)
49. Raad, I., R. Darouiche, J. Vazquez, A. Lentnek, R. Hachem, H. Hanna, B. Goldstein, T. Henkel, and E. Seltzer. 2005. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 40:374-380.
50. Robert, J., R. Bismuth, and V. Jarlier. 2006. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57:506-510.
51. Rolston, K. V., G. P. Bodey, and A. W. Chow. 1999. Prospective, doubleblind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens. J. Infect. Chemother. 5:208-212.
52. Rolston, K. V., H. Nguyen, G. Amos, L. Elting, V. Fainstein, and G. P. Bodey. 1994. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J. Infect. Dis. 169:350-355.
53. Rubinstein, E., G. R. Corey, H. W. Boucher, M. S. Niederman, A. F. Shorr, A. Torres, B. S. L., H. D. Friedland, and O. B. O. T. A. S. Group. 2008. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet., abstr. K-529. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
54. Rubinstein, E., G. R. Corey, M. E. Stryjewski, H. W. Boucher, R. N. Daly, F. C. Genter, B. S. L., M. M. Kitt, and H. D. Friedland. 2008. Abstr. 18th Eur. Congr. Clin. Microbiol. Infect. Dis., abstr. 075.
55. Rubinstein, E., G. R. Corey, M. E. Stryjewski, J. L. Vincent, J. Y. Fagon, M. H. Kollef, M. M. Kitt, and H. D. Friedland on behalf of the Attain Study Group. 2008. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet., abstr. K-530. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
56. Rybak, M., B. Lomaestro, J. C. Rotschafer, R. Moellering, Jr., W. Craig, M. Billeter, J. R. Dalovisio, and D. P. Levine. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
57. Rybak, M. J., E. M. Bailey, and L. H. Warbasse. 1992. Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin. Antimicrob. Agents Chemother. 36:1204-1207.
58. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
59. Seltzer, E., M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell, and T. Henkel. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37:1298-1303.
60. Sidi, V., E. Roilides, E. Bibashi, N. Gompakis, A. Tsakiri, and D. Koliouskas. 2000. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia. J. Chemother. 12:326-331. (Pubitemid 30640386)
61. Sievert, D. M., J. T. Rudrik, J. B. Patel, L. C. McDonald, M. J. Wilkins, and J. C. Hageman. 2008. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46:668-674.
62. Smith, S. R., J. Cheesbrough, R. Spearing, and J. M. Davies. 1989. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob. Agents Chemother. 33:1193-1197.
63. Soriano, A., F. Marco, J. A. Martinez, E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, and J. Mensa. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
64. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin- susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794.
65. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallee, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by grampositive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867.
66. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.
67. Stryjewski, M. E., W. D. O'Riordan, W. K. Lau, F. D. Pien, L. M. Dunbar, M. Vallee, V. G. Fowler, Jr., V. H. Chu, E. Spencer, S. L. Barriere, M. M. Kitt, C. H. Cabell, and G. R. Corey. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. 40:1601-1607.
68. Styers, D., D. J. Sheehan, P. Hogan, and D. F. Sahm. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5:2.
69. Tacconelli, E., M. Tumbarello, K. G. Donati, M. Bettio, T. Spanu, F. Leone, L. A. Sechi, S. Zanetti, G. Fadda, and R. Cauda. 2001. Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study. Clin. Infect. Dis. 33:1628-1635.
70. Tenover, F. C., and R. C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215.
71. Van der Auwera, P., M. Aoun, and F. Meunier. 1991. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob. Agents Chemother. 35:451-457.
72. Van Laethem, Y., P. Hermans, S. De Wit, H. Goosens, and N. Clumeck. 1988. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J. Antimicrob. Chemother. 21(Suppl. A):81-87.
73. Vazquez, L., M. P. Encinas, L. S. Morin, P. Vilches, N. Gutierrez, R. Garcia-Sanz, D. Caballero, and A. D. Hurle. 1999. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Haematologica 84: 231-236. (Pubitemid 29476927)
74. Walsh, T. R., A. Bolmstrom, A. Qwarnstrom, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
75. Wasilewski, M. M., D. P. Disch, J. M. McGill, H. W. Harris, W. O'Riordan, and M. L. Zeckel. 2001. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. UL-18.
76. Wood, M. J. 1996. The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother. 37:209-222.
77. Zhao, W. F., C. H. Ling, and X. F. Zhang. 2003. A randomized controlled clinical trial of teicoplanin versus vancomycin in the treatment of severe gram-positive bacterial infections. Jiangsu Med. J. 29:913-915.